Shots:
- Dr. Reddy’s to receive $40M up front upon the closing of the transaction, followed by ~$40M milestones on E7777’s approval in CTCL and ~$70M for additional indication approvals. Additionally, Dr. Reddy’s will receive commercial milestones and royalties
- Citius to get all the rights to E7777 (an engineered IL-2-diphtheria toxin fusion protein) and certain related assets
- Dr. Reddy’s had acquired the exclusive global rights (Ex-Japan and Asia) to the investigational anti-cancer agent, E7777 from Eisai in Mar’2016
Click here to read full press release/ article | Ref: Businesswire | Image: Dr. Reddy’s
The post Dr. Reddy’s Collaborates with Citius to Sell Rights of its Anti-Cancer Agent (E7777) first appeared on PharmaShots.
